(Q37707419)

22 August 2017

1 reference

title

Benefits of and safety concerns associated with drug-eluting coronary stents (English)

1 reference

22 August 2017

2

Patrick Serruys

1 reference

22 August 2017

1

Scot Garg

1 reference

22 August 2017

publication date

1 March 2010

1 reference

Expert Review of Cardiovascular Therapy

22 August 2017

published in

1 reference

22 August 2017

volume

8

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

449-470

1 reference

Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Patterns and outcomes of drug-eluting coronary stent use in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Transluminal dilatation of coronary-artery stenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Angiographic follow-up after placement of a self-expanding coronary-artery stent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Intracoronary stenting without coumadin: one month results of a French multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Late acute thrombosis after paclitaxel eluting stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Late stent thrombosis after implantation of a sirolimus‐eluting stent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

A critical appraisal of the safety and efficacy of drug-eluting stents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Stent thrombosis redux--the FDA perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

A comparison of bare-metal and drug-eluting stents for off-label indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Clinical end points in coronary stent trials: a case for standardized definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Stent thrombosis in randomized clinical trials of drug-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Endothelial cell recovery between comparator polymer-based drug-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Ar

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: acute and 9-month intravascular ultrasound results of the MISSION! intervention study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Intravascular ultrasound findings during episodes of drug-eluting stent thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Impact of a prolonged delivery inflation time for optimal drug-eluting stent expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

What to do about late incomplete stent apposition?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris: a serial optical coherence tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Randomized trial on routine vs. provisional T-stenting in the treatment of de novo coronary bifurcation lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Randomized comparison of coronary bifurcation stenting with the crush versus the culotte technique using sirolimus eluting stents: the Nordic stent technique study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Impact of complete revascularization with percutaneous coronary intervention on survival in patients with at least one chronic total occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Five-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital-(Research) Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Sirolimus-eluting versus uncoated stents in acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Antiplatelet therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Early and late effects of clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Impact of a 600-mg loading dose of clopidogrel on 30-day outcome in unselected patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patien

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Coronary stents and noncardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Unplanned surgery after drug eluting stent implantation: a strategy for safe temporary withdrawal of dual oral antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Effectiveness of primary percutaneous coronary interventions for stent thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Effectiveness and safety of drug-eluting stents in Ontario.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Safety of drug-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Optimal medical therapy with or without PCI for stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Ticagrelor--is there need for a new player in the antiplatelet-therapy field?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

Safety and Effectiveness of Drug-Eluting and Bare-Metal Stents for Patients With Off- and On-Label Indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.09.138

21 January 2018

Identifiers

DOI

10.1586/ERC.09.138

1 reference

22 August 2017

1 reference